The CD39+ Tregs sorted from BPH patients showed more potent of suppressive capacity than CD39− Tregs, as demonstrated by inhibition of responder cell proliferation at a ratio of responder cells: Tregs of 10:1 (proliferation of CD39+Tregs 47.96 ± 27.51% vs proliferation of CD39− Tregs 78.66 ± 25.61%, Figure 2D). The gene discussed is ENTPD1; the disease is benign prostatic hyperplasia.